Galvanize Therapeutics Raises $130M Series D to Destroy Diseased Tissue With Electricity, Not Heat
Instead of cutting tissue out or burning it away, medical device company Galvanize Therapeutics destroys diseased tissue with electrical pulses. It has closed a $130 million Series D as it works to extend the technology to cancer and chronic lung disease. HealthQuest Capital, a growth investor in commercial-stage healthcare companies, led the round. Olympus Innovation Ventures, the venture arm of endoscope maker Olympus, and investment firm Braidwell LP joined as new investors.

Electricity instead of heat
There are roughly three ways to remove diseased tissue such as a tumor: surgery that cuts it out, treatments that burn or freeze it, and electrical pulses. Galvanize takes the third path. A thin needle is placed in the lesion, and short, strong pulses of electricity cause the cells to die on their own.
The absence of heat is the point. Heat-based treatments can damage healthy tissue around the lesion, and the industry hopes pulsed electric field (PEF) treatment is less likely to. It also needs no open surgery, since the needle is reached through the skin or an endoscope. The technology is already commercial in heart rhythm treatment, and Galvanize has brought it to tumors.
The main product is the Aliya PEF System, which has FDA 510(k) clearance as a tool for destroying soft tissue. The clearance covers soft-tissue ablation, not the treatment of any specific cancer. This year the next-generation Aliya EX generator won clearance and launched commercially. It can treat a zone about 20 millimeters across, compared with about 10 for the older device, which widens the range of patients. The INUMI Flex needle, part of the same system, is passed through an endoscope to reach lesions that are hard to get at from outside the body.
The company says more than 4,000 procedures have been performed, and its PROPEL registry has enrolled more than 300 patients. Over 40 peer-reviewed papers cover how PEF works and how patients fare. Preclinical and early clinical data also hint that the procedure may activate the immune system, but a benefit to patients from an immune response has not been established.
A second front in chronic bronchitis
The money will go to commercial expansion of Aliya, clinical evidence and next-generation PEF products, and also to RheOx. RheOx sends electrical pulses to the airways of people with chronic bronchitis to reduce the cells that produce excess mucus. In the disease, sticky mucus keeps building up in the airways, causing a persistent cough and phlegm. RheOx is certified in Europe and holds an FDA breakthrough device designation in the US, but it is not yet approved there. Enrollment is complete in RheSolve, a 270-patient trial in people with chronic obstructive pulmonary disease (COPD), and results have not been released.
Born from a merger, funded twice at scale
Galvanize was formed in 2022 through a merger with Gala Therapeutics and Galaxy Medical. In September 2025 it closed a $100 million Series C led by Sofinnova Partners and brought in Doug Godshall as chairman and CEO. In the Series D, Sofinnova, Norwest, Elevage Medical Technologies, Ally Bridge Group, Perceptive Advisors, Janus Henderson Investors, Longaeva Partners, Fidelity Management & Research and T. Rowe Price took part as existing investors. The company did not disclose a valuation or total funding.
Garheng Kong, MD, PhD, HealthQuest’s founder and managing partner, will join the board. Kong said Galvanize has a differentiated PEF platform with the potential to advance care in interventional oncology and pulmonology. Godshall said Aliya has built physician adoption and clinical evidence, and that it is time to extend PEF across cancer and chronic disease.
Competition: the PEF fight is still mostly in the heart
Pulsed field procedures are most active in cardiology. Boston Scientific‘s Farapulse and Medtronic‘s PulseSelect already use the technology to treat atrial fibrillation. In tumors, AngioDynamics, maker of the NanoKnife system that destroys cells with electrical shocks, has FDA clearance for prostate tissue ablation, and since July a US Medicare contractor has covered the approach for intermediate-risk prostate cancer and for colorectal cancer that has spread to the liver. Pulse Biosciences pursued a first-in-human feasibility study in thyroid cancer with its own pulse technology but is now focused on a cardiac catheter.
Galvanize is going after the gap between them: lesions reachable by endoscope, and chronic lung disease. Procedure counts and clinical results are the company’s own and have not been independently verified.
MORE FROM THE POST
- Science Raises $400M Series D as PRIMA Sight-Restoring Implant Eyes US Launch
- Cancer Interception Vaccine Maker Nouscom Raises $135M Series D
- 3D-Printing Construction Robotics Firm ICON Raises $200M Series D
- Biomolecular AI Startup Boltz Raises $110M Series A Led by Bessemer
- AI Drug Design Lab Isomorphic Labs Raises $5B Series C
- BioHealth
- funding
- Galvanize Therapeutics
- HealthQuest Capital
- Norwest
- Overseas funding
- seriesD
- Sofinnova Partners
Share
Most Read
- 1
- 2
- 3
- 4
- 5


Leave a Reply